natgillin/translations-raw huggingface dataset:
An improvement of 20% was seen in 52% of the subjects receiving rotigotine, 68% of the subjects receiving ropinirole and 30% of the subjects receiving placebo (Difference rotigotine versus placebo 21.7%, CI95% 11.1%; 32.4%, difference ropinirole versus placebo 38.4%, CI95% 28.1%; 48.6%, difference ropinirole versus rotigotine 16.6%, CI95% 7.6%; 25.7%).
20-odstotno izboljšanje so opazili pri 52 % bolnikov, ki so prejemali rotigotin, 68 % bolnikov, ki so prejemali ropinirol, in pri 30 % bolnikov, ki so prejemali placebo (razlika med rotigotinom in placebom je bila 21,7 %; CI95% 11,1 % - 32,4 %; razlika med ropinirolom in placebom je bila 38,4 %, CI95% 28,1 %- 48,6 %; razlika med ropinirolom in rotigotinom je bila 16,6 %, CI95% 7,6 % - 25,7 %).
An in vitro 3T3 test showed that afatinib may have phototoxicity potential.
In vitro preskus 3T3 je pokazal, da ima afatinib lahko fototoksične učinke.
An in vitro study indicated a low potential for interaction between levofloxacin and CYP2C9 substrates.
Študija in vitro je pokazala nizek potencial za interakcije med levofloksacinom in substrati CYP2C9.
An in vitro study indicates that drug-drug interactions are unlikely to occur at therapeutic doses as a result of induction by bosutinib on the metabolism of medicinal products that are substrates for CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4.
Študija in vitro je pokazala, da je pri terapevtskih odmerkih majhna verjetnost za medsebojno delovanje z drugimi zdravili, ki bi se pojavilo zaradi indukcije (ki jo povzroča bosutinib) metabolizma zdravil, ki so substrati CYP1A2, CYP2B6, CYP2C9, CYP2C19 in CYP3A4.
An in vitro study of azacitidine with cultured human hepatocytes indicates that at concentrations of 1.0 µM to 100 µM (i.e. up to approximately 30-fold higher than clinically achievable concentrations), azacitidine does not induce CYP 1A2, 2C19, or 3A4 or 3A5.
In vitro študija z gojenimi humanimi hepatociti kaže, da pri koncentraciji 1,0 µM do 100 µM (t.j. do približno 30-krat višje kot klinično dosegljive koncentracije) azacitadin ne inducira CYP 1A2, 2C19, 3A4 ali 3A5.
An in vivo interaction study with leflunomide and cimetidine (non-specific weak cytochrome P450 (CYP) inhibitor) has demonstrated a lack of a significant impact on A771726 exposure.
Študija interakcij z leflunomidom in cimetidinom (nespecifičnim zaviralcem citokroma P450) in vivo ni pokazala pomembnega vpliva na izpostavljenost A771726.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo.
Interakcijska študija z varfarinom in vivo je pokazala, da rosiglitazon in vivo nima medsebojnega delovanja s substrati CYP2C9.
An in-built lock-out mechanism which controls how often the nasal spray can be used
vgrajen mehanizem za zaklepanje proženja, ki nadzira, kako pogosto se pršilo lahko uporabi;
An increase from baseline in corrected QT interval by Fridericia (QTcF) of 10 – 15 ms on Day 29 (but not on Day 1) following initiation of cabozantinib treatment (at a dose of 140 mg qd) was observed in a controlled clinical study in medullary thyroid cancer patients.
V kontroliranih kliničnih študijah pri bolnikih z medularnim rakom ščitnice so opazili zvišanje od izhodišča popravljenega intervala QT z metodo po Fridericiju (QTcF) za 10 – 15 ms na 29. dan (vendar ne na 1. dan) po uvedbi zdravljenja s kabozantinibom (odmerek 140 mg enkrat na dan).
An increase from baseline in serum creatinine solely due to cobicistat’s inhibitory effect generally does not exceed 0.4 mg/dl.
Povečanje vrednosti kreatinina v serumu od izhodišča, ki je izključno posledica zaviralnega učinka kobicistata, na splošno ne presega 0,4 mg/dl.
An increase from baseline in serum creatinine solely due to cobicistat’s inhibitory effect generally does not exceed 0.4 mg/dl.
Zvišanje serumskega kreatinina samo zaradi zaviralnega učinka kobicistata v primerjavi z izhodiščnimi vrednostmi v splošnem ne preseže 0,4 mg/dl.
an increase in a substance which may be found in blood tests when muscles are inflamed or damaged kidney failure, passing protein in urine
povečana količina snovi, ki je lahko prisotna v izvidih krvi pri vnetih ali poškodovanih mišicah odpoved ledvic, izločanje proteinov z urinom
An increase in alkaline phosphatase (an enzyme found in the body)
zvišane vrednosti alkalne fosfataze (encim v telesu);
an increase in an enzyme called amylase a failure of the bone marrow to produce new red blood cells (pure red cell aplasia).
zvišanje encima, imenovanega amilaza, nezmožnost kostnega mozga za tvorbo novih rdečih krvnih celic (čista aplazija rdečih celic).
An increase in blood pressure, reduced or increased heart rate and limb or back pain may also be possible.
Prav tako se lahko pojavijo povišanje krvnega tlaka, počasen ali hiter srčni utrip in bolečine v okončinah ali hrbtu.
An increase in blood-test results that show how your liver is working Other side effects reported with eye drops containing phosphates
Drugi neželeni učinki kapljic za oko, ki vsebujejo fosfate
An increase in body temperature up to about 40.5°C can occur in a small number of pigs, lasting for up to two days.
Pri manjšem številu prašičev lahko telesna temperatura naraste do približno 40,5°C. Tako stanje lahko traja do dva dni.
An increase in body temperature within the physiological range is common within 4 hours of vaccination and spontaneously resolves within 24 hours.
Pogost je porast telesne temperature znotraj fiziološkega razpona v 4 urah po cepljenju, ki v 24 urah sam od sebe izzveni.
An increase in both the rate and extent of systemic exposure was observed for the elderly population when compared to the young population.
Pri starejši populaciji so opazili hitrejšo in obsežnejšo sistemsko izpostavljenost v primerjavi z mlajšo populacijo.
An increase in cholesterol and triglyceride levels has been associated with thiazide diuretic therapy; however, at the 12.5 mg dose contained in Actelsar HCT, minimal or no effects were reported.
Z zdravljenjem s tiazidnimi diuretiki povezujejo povečanje ravni holesterola in trigliceridov, vendar za odmerek po 12,5°mg, ki ga vsebuje zdravilo Actelsar HCT, poročajo le o minimalnih ali nikakršnih tovrstnih učinkih.
An increase in creatininemia should not necessarily lead to the discontinuation of treatment with ACE inhibitors or Angiotensin II Receptors Antagonists (AIIRAs).
Porast kreatininemije ni nujno razlog za prenehanje zdravljenja z zaviralci ACE ali antagonisti receptorjev angiotenzina II.
An increase in dose from 750 mg every 8 hours to 1,875 mg every 8 hours in a multiple-dose study resulted in a less than proportional increase (i.e., about 40%) in telaprevir exposure.
Zvečanje odmerka v študiji uporabe večkratnih odmerkov s 750 mg na 8 ur na 1.875 mg na 8 ur je vodilo do zvečanja izpostavljenosti telaprevirju, ki je bilo za približno 40% manjše od premosorazmernega.
An increase in gout flares is frequently observed when starting KRYSTEXXA.
Pri uvedbi zdravila KRYSTEXXA so pogosto opazili povečanje napadov protina.
An increase in heparin dose during haemodialysis is frequently required during the course of therapy with erythropoietin as a result of the increased packed cell volume.
Pri hemodializi je med zdravljenjem z zdravilom Retacrit, zaradi povečanega hematokrita treba pogosto povečati odmerek heparina.
An increase in levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur, particularly when starting treatment.
Lahko se zvišajo ravni majhnih krvnih celic (ki se imenujejo trombociti), ki običajno sodelujejo pri nastajanju krvnih strdkov, zlasti ob začetku zdravljenja.
an increase in methaemoglobin (an abnormal form of haemoglobin in the blood)
zvišanje ravni methemoglobina (nenormalne oblike hemoglobina v krvi)
an increase in methaemoglobin (an abnormal form of haemoglobin in the blood),
zvišanje ravni methemoglobina (nenormalne oblike hemoglobina v krvi),
An increase in pneumonia has been observed in patients with COPD receiving fluticasone furoate/vilanterol.
Pri bolnikih s KOPB, ki so prejemali flutikazonfuroat/vilanterol, so ugotovili več pljučnic.
an increase in protein in the urine, an increase in cholesterol in the blood, and swelling from excess fluid (oedema) (also called ‘nephrotic syndrome’) blood clot in very small blood vessels (also called ‘thrombotic microangiopathy’).
zvišanje beljakovin v urinu, zvišanje holesterola v krvi in otekanje zaradi prekomerne tekočine (edemi) (to imenujemo tudi "nefrotski sindrom") krvni strdki v zelo majhnih žilah (to imenujemo tudi "trombotična mikroangiopatija").
An increase in red blood cell mass may increase the risk of embolic and thrombotic events.
Povečanje mase rdečih krvničk lahko poveča tveganje za pojav emboličnih in trombotičnih dogodkov.
an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice,
zvišanje nekaterih vrednosti jetrnih testov, kar se lahko razvije v resne bolezni, npr. hepatitis in zlatenico,
an increase in some liver test results,
zvišanje nekaterih vrednosti jetrnih testov,
An increase in some liver test results. problems in the nerves of the arms or legs (peripheral neuropathy).
povišanje rezultatov nekaterih jetrnih testov, težave z živci rok ali nog (periferna nevropatija).
An increase in still-born pups and decrease in post-natal viability of pups was observed in pre- postnatal toxicity studies in rats.
Povečanje mrtvorojenih mladičev in zmanjšanje postnatalnega preživetja mladičev so opazili v študijah pre - in postnatalne toksičnosti pri podganah.
an increase in sugar (glucose) in the blood an increase in triglycerides (type of fat) in the blood
povišana vrednost sladkorja (glukoze) v krvi povišana vrednost trigliceridov (vrsta maščobe) v krvi
an increase in the amount of potassium in the blood changes in the rhythm of the heart, or the heart beating faster than normal
povečanje količine kalija v krvi, spremembe v srčnem ritmu ali hitrejše (kot je običajno) bitje srca.
An increase in the amount of sugar (glucose) in your blood.
zvišan sladkor (glukoza) v krvi,
An increase in the concentration of enoxaparin sodium after using prophylactic doses (non-weight adjusted) has been observed in low-weight female patients (<45 kg) and low-weight male patients (<57 kg), which may lead to a higher risk of bleeding.
Pri ženskah z majhno telesno maso (< 45 kg) in moških z majhno telesno maso (< 57 kg) so po uporabi profilaktičnih odmerkov (ki niso prilagojeni glede na telesno maso) opazili povečane koncentracije natrijevega enoksaparinata, kar lahko poveča tveganje za krvavitev.
An increase in the concentration of enoxaparin sodium after using prophylactic doses (non-weight adjusted) has been observed in low-weight female patients (<45 kg) and low-weight male patients (<57 kg), which may lead to a higher risk of bleeding.
Pri ženskah z majhno telesno maso (< 45 kg) in moških z majhno telesno maso (< 57 kg) so po uporabi profilaktičnih odmerkov (ki niso prilagojeni na telesno maso) opazili povečane koncentracije natrijevega enoksaparinata, kar lahko poveča tveganje za krvavitev.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Retacrit to minimize the risk of blood clotting.
Zvišanje odmerka zdravila za redčenje krvi (heparina) med hemodializo je pri zdravljenju z zdravilom Retacrit dostikrat potrebno, ker se z njim zmanjšuje možnost strdkov v krvi.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Silapo to minimize the risk of blood clotting.
Zvišanje odmerka zdravila za redčenje krvi (heparina) med hemodializo je pri zdravljenju z zdravilom Silapo dostikrat potrebno, ker se z njim zmanjšuje možnost strdkov v krvi.
An increase in the dose of lopinavir/ritonavir to 533/133 mg (4 capsules) or 500/125 mg (5 tablets with 100/25 mg each) twice daily with food is recommended in combination with Nevirapine Teva.
Pri kombiniranju z zdravilom Nevirapin Teva se priporoča povečanje odmerka lopinavir/ ritonavir do 533/133 mg (4 kapsule) ali 500/125 mg (5 tablet po 100/25 mg) 2-krat na dan ob jedi.
An increase in the incidence in trazodone- related adverse events was noted when coadministered with ritonavir.
Pri sočasnem dajanju z ritonavirjem so ugotovili povečano incidenco neželenih učinkov, povezanih s trazodonom.
An increase in the incidence in trazodone-related adverse reactions was noted when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Med sočasno uporabo trazodona z ritonavirjem, odmerjanim kot protiretrovirusno zdravilo ali farmakokinetični stopnjevalec, so opažali večjo incidenco neželenih učinkov, povezanih s trazodonom.
an increase in the incidence of
pogostnosti neželenih učinkov,
an increase in the level of liver enzymes a decrease in the number of cells involved in blood clotting (thrombocytopenia).
povečane vrednosti jetrnih encimov; zmanjšanje števila krvnih celic, ki so pomembne pri strjevanju krvi (trombocitopenija).
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow
zvišanje jetrnih encimov, zvišanje bilirubina (snovi, ki nastaja v jetrih) v krvi, zaradi česar se lahko pojavi porumenelost kože.
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow.
povečane vrednosti jetrnih encimov, povečana količina belirubina (snov, ki nastaja v jetrih) v krvi, ki lahko povzroči rumeno obarvanje kože.
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow.
povečane vrednosti jetrnih encimov, povečana količina bilirubina (snov, ki nastaja v jetrih) v krvi, ki lahko povzroči rumeno obarvanje kože.
an increase in the levels of fat in the blood (cholesterol and triglycerides), a decrease in the levels of phosphate in the blood.
zvečanje koncentracije maščob v krvi (holesterola in trigliceridov), zmanjšanje koncentracije fosfata v krvi.
An increase in the levels of fat in the blood (cholesterol and triglycerides).
zvečanje koncentracije maščob v krvi (holesterola in trigliceridov),
An increase in the number of blood cells called eosinophiles (eosinophilia).
zvečanje števila krvnih celic imenovanih eozinofilci (eozinofilija),
an increase in the number or proportion of white blood cells shown in blood tests
povečano število ali delež belih krvnih celic v izvidih preiskav krvi
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
zvečanje števila krvnih celic imenovanih eozinofilcev (eozinofilija), blago zmanjšanje števila belih krvnih celic (levkopenija); zmanjšanje števila vseh krvnih celic (pancitopenija),
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
zvečanje števila krvnih celic imenovanih eozinofilci (eozinofilija), blago zmanjšanje števila belih krvnih celic (levkopenija); izmanjšanje števila vseh krvnih celic (pancitopenija).
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
zvečanje števila krvnih celic imenovanih eozinofilci (eozinofilija), blago zmanjšanje števila belih krvnih celic (levkopenija); zmanjšanje števila vseh krvnih celic (pancitopenija),
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
zvečanje števila krvnih celic imenovanih eozinofilci (eozinofilija); blago zmanjšanje števila belih krvnih celic (levkopenija); zmanjšanje števila vseh krvnih celic (pancitopenija),
An increase in the occurrence of blood clots has been observed.
Opazili so porast v pojavu krvnih strdkov.
an increase in the thickness in the mouth or tongue;
zadebelitev ust ali jezika,
An increase in uric acid and indirect bilirubin values associated with haemolysis was observed in some patients treated with Ribavirin Teva Pharma B.V. used in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials, but values returned to baseline levels by four weeks after the end of therapy.
Pri nekaterih bolnikih, ki so bili zdravljeni z zdravilom Ribavirin Teva Pharma B.V. v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b v kliničnih preskušanjih, so opažali zvečanje vrednosti sečne kisline in indirektnega bilirubina v povezavi s hemolizo, vendar so se te vrednosti povrnile na začetne vrednosti do konca četrtega tedna po koncu terapije.
An increase in uric acid and indirect bilirubin values associated with haemolysis was observed in some patients treated with ribavirin used in combination with peginterferon alfa-2b or interferon alfa- 2b in clinical trials, but values returned to baseline levels by four weeks after the end of therapy.
Pri nekaterih bolnikih, ki so bili zdravljeni z ribavirinom v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b v kliničnih preskušanjih, so opažali zvečanje vrednosti sečne kisline in indirektnega bilirubina v povezavi s hemolizo, vendar so se te vrednosti povrnile na začetno raven v štirih tednih po koncu terapije.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral theraphy.
Med protiretrovirusnim zdravljenjem se lahko poveča telesna masa ter zviša koncentracija lipidov in glukoze v krvi.
An increase in your serum creatinine level (problems with your kidneys),
zvišanje ravni serumskega kreatinina (težave z ledvicami),
an increase in your weight blood pressure dropping upon your standing up which may cause fainting.
če imate prekomerno telesno maso če imate težave z nenadnim znižanjem krvnega tlaka po vstajanju iz sedečega ali ležečega položaja, kar lahko povzroči omedlevico.
An increase of > 3 x ULN in alanine aminotransferase or aspartate aminotransferase was recorded in 12.8% of subjects in the cobicistat- boosted group and 9.0% in the ritonavir-boosted group.
Povečanje za > 3 x ULN alanin aminotransferaze ali aspartat aminotransferaze so zabeležili pri 12,8 % bolnikov v skupini zdravila, okrepljenega s kobicistatom, in 9,0 % v skupini zdravila, okrepljenega z ritonavirjem.
An increase of blood pressure, bradycardia or tachycardia and limb or back pain might be possible.
Pojavijo se lahko tudi povišanje krvnega tlaka, bradikardija ali tahikardija in bolečine v okončinah ali hrbtu.
an increase of certain enzymes in the blood (creatine phosphokinase), problems in the nerves of the arms or legs (peripheral neuropathy).
zvišanje določenih encimov v krvi (kreatin-fosfokinaza), težave z živci rok ali nog (periferna nevropatija).
an increase of certain enzymes in the blood (creatine phosphokinase), problems in the nerves of the arms or legs (peripheral neuropathy).
zvišanje določenih encimov v krvi (kreatin-fosfokinaza). težave z živci rok ali nog (periferna nevropatija).
An increase of certain enzymes in the blood (creatine phosphokinase).
zvišanje določenih encimov v krvi (kreatin-fosfokinaza),
an increase of certain enzymes in theblood (creatinephosphokinase), problems in the nerves of the arms or legs (peripheral neuropathy).
zvišanje določenih encimov v krvi (kreatin-fosfokinaza), težave z živci rok ali nog (periferna nevropatija).
An increase of frequency and severity of some adverse reactions was observed, mainly diarrhoea and skin rash.
Opažali so večjo pogostnost in izrazitost nekaterih neželenih učinkov, predvsem driske in kožnega izpuščaja.
an increase of Kaletra dosage may
Kaletra in pričnejo z uporabo
An increase of lactate dehydrogenase (a blood enzyme).
zvišanje laktat-dehidrogenaze (encim v krvi),
An increase of non- Hodgkin’s lymphoma growth was noted after a continuous administration of plerixafor for 28 days.
Povečano rast ne- Hodgkinovega limfoma so zabeležili po 28-dnevnem neprekinjenem dajanju pleriksaforja.
An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
V kliničnih preskušanjih predhodno zdravljenih bolnikov s plazmocitomom, ki so prejemali lenalidomid /deksametazon, so opazili povečanje drugih primarnih malignosti (SPM - second primary malignancies) (3,98 na 100 oseb-let) v primerjavi s kontrolnimi skupinami (1,38 na 100 oseb-let).
An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
V kliničnih preskušanjih predhodno zdravljenih bolnikov s plazmocitomom, ki so prejemali lenalidomid/deksametazon, so opazili povečanje drugih primarnih malignosti (SPM – second primary malignancies) (3,98 na 100 oseb-let) v primerjavi s kontrolnimi skupinami (1,38 na 100 oseb-let).
An increase of ≥1 g/dL change in Hb at Week 12 was achieved in 90 % and 69 % of the ulcerative colitis (N=29) and Crohn’s Disease (N=35) subgroups, respectively.
Povečanje vrednosti Hb za ≥ 1 g/dl v 12. tednu je doseglo 90 % bolnikov v podskupini z ulcerativnim kolitisom (N = 29) in 69 % bolnikov v podskupini s Crohnovo boleznijo (N = 35).
An increase of ≥2 g/dL change in Hb at Week 12 was achieved in 62 % and 51 % of the ulcerative colitis and Crohn’s Disease subgroups, respectively.
Povečanje vrednosti Hb za ≥ 2 g/dl v 12. tednu je doseglo 62 % bolnikov v podskupini z ulcerativnim kolitisom in 51 % bolnikov v podskupini s Crohnovo boleznijo.
An increased 3H-thymidine incorporation in the erythroid nucleated spleen cells has been found in vitro (mouse spleen cell culture) after incubation with epoetin beta.
V in vitro pogojih (celična kultura mišje vranice) so ugotovili povečan obseg vgrajevanja H-timidina v eritroidne vranične celice z jedrom.
An increased dose (1,000 mg TID) of indinavir
(indinavir 1000 mg TID)
An increased drug half-life has been observed in patients with severe hepatic impairment, possibly related to increased tissue distribution.
Pri bolnikih s hudo okvaro jeter so opazili podaljšan razpolovni čas zdravila, ki je verjetno povezan s povečano porazdelitvijo v tkivih.
An increased drug half-life has however been observed in patients with severe hepatic impairment (see section 4.4 and 5.2).
Vseeno so pri bolnikih s hudo okvaro jeter opazili podaljšan razpolovni čas zdravila (glejte poglavje 4.4 in 5.2).
An increased frequency was noted when empagliflozin given as add-on to metformin and a sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5% and placebo: 8.4%) or as add-on to metformin and insulin (empagliflozin 10 mg: 31.3%, empagliflozin 25 mg: 36.2% and placebo:
Večjo pogostnost so opazili pri uporabi empagliflozina kot dodatnega zdravljenja k metforminu in sulfonilsečnini (empagliflozin 10 mg: 16,1 %, empagliflozin 25 mg: 11,5 %, placebo: 8,4 %) ali kot dodatnega zdravljenja k metforminu in insulinu (empagliflozin 10 mg: 31,3 %, empagliflozin 25 mg: 36,2 % in placebo: 34,7 %).
An increased frequency was noted when given as add-on to insulin with or without metformin and with or without a sulfonylurea (empagliflozin 10 mg: 0%, empagliflozin 25 mg: 1.3%, placebo: 0% during initial 18 weeks treatment when insulin could not be adjusted; empagliflozin 10 mg: 0%, empagliflozin 25 mg: 1.3%, placebo 0% over the 78-week trial).
Večjo pogostnost so opazili pri uporabi kot dodatno zdravljenje z insulinom z metforminom ali brez njega ali s sulfonilsečnino ali brez nje (empagliflozin 10 mg: 0 %, empagliflozin 25 mg: 1,3 %, placebo: 0 % v prvih 18 tednih zdravljenja, ko insulina ni bilo mogoče prilagoditi; empagliflozin 10 mg: 0 %, empagliflozin 25 mg: 1,3 %, placebo 0 % v 78-tedenskem preskušanju).